Kennedy announced last week that the administration was canceling 22 mRNA vaccine development ... citing their effectiveness ...

The rollback of vaccine record retention requirements was announced by the Office of Personnel Management (OPM) in a memo to ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday. The updated shot targets the LP.8.1 variant, ...

The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024.

Pfizer reported its mRNA vaccine was more than 90% effective in protecting against COVID-19 disease, but it’s important to understand what effectiveness means in their and Moderna’s studies.

Moderna's candidate COVID-19 vaccine is even more effective than Pfizer's, trial results show, a "light at the end of the tunnel" for the pandemic.

Moderna’s Covid Vaccine: What You Need to Know Denise Grady Published Nov. 16, 2020 Updated Nov. 30, 2020 Share full article ...

COVID vaccine maker Pfizer Inc. lost 0.6%, while its partner BioNTech, shed 3.8%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.

Moderna's trial of a new COVID-19 vaccine will target the virus variant that first emerged in South Africa. Other vaccine makers plan similar studies.

Interim results of a Phase 2/3 trial showed Moderna’s Covid-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said Monday.

Moderna's COVID-19 Vaccine Shines In Clinical Trial Overall, the study identified 185 cases in the people who received a placebo shot, compared with 11 cases in people who got the active vaccine.